Presented at #ASH24: Among patients with smoldering multiple myeloma at a high risk for progression, progression-free survival at 5 years was 63.1% with daratumumab monotherapy, as compared with 40.8% with active monitoring. Full AQUILA trial results: nej.md/3Zh3pOJ

The Mayo Clinic myeloma group at #ASH24 @MayoMyeloma Many others are hard at work back home in Rochester, Arizona, and Florida. Moritz Binder, Morie Gertz Rafael Fonseca MD 🦔🇺🇸🏜🇲🇽 Angela Dispenzieri Suzanne Hayman et al.

This is the first study investigating the prognostic value of #MRD assessment in relapsed/refractory multiple #myeloma patients treated with CAR T-cells and TCE doi.org/10.1002/ajh.27… Bruno Paiva

The largest experience of autologous hematopoietic cell transplantation in 1700 patients with autoimmune diseases, in the outpatient setting, using the “Mexican method”. “Yes, it can be done” “Si se puede”Bone Marrow Transplantation Guillermo J. Ruiz-Argüelles David Gómez-Almaguer Andres Gomez

The fascinating story of Thalidomide: how this most notorious drug on the planet, banned in the 1960s, made an incredible comeback and revolutionized the treatment of myeloma. I will also highlight one person whose role is not recognized: Without Dr. Leif Bergsagel there will

#Myeloma Paper of the Day: Study of real world outcomes with elotuzumab-based therapies for relapsed & refractory myeloma finds median PFS for EPd was 4.8 months and for ERd was 17.28 months; median OS 2.55 and was 5.64 years, respectively: pubmed.ncbi.nlm.nih.gov/40410136/. #mmsm

#Myeloma Paper of the Day: Study of attrition rates & treatment outcomes in myeloma finds they declined from 38-55% in 1980s to 15-20% in 2010-2020, but remain high in older patients, with 46.9% of those over 80 unable to proceed beyond first LOT: pubmed.ncbi.nlm.nih.gov/40419498/. #mmsm

Screening for monoclonal gammopathy of undetermined significance is contraindicated buff.ly/13LCjeJ

Vincent Rajkumar Mayo Myeloma While many #CART centers are proficient in managing CRS & ICANS, we are all learning how best to evaluate & manage emerging late toxicities in the field. Fortunate to have ANASTASIA ZEKERIDOU and Navreet Chowla, MD, FACG bring their team expertise. Stay tuned for updates as we learn more.

#mmsm Journal of Clinical Oncology New definition of high risk multiple myeloma by IMWG ➡️ascopubs.org/doi/10.1200/JC… Summary 👇

We are happy to share our recently published clinical practice recommendations on the role of allogeneic hematopoietic cell transplantation and CAR T-cell therapy in chronic lymphocytic leukemia on behalf of #ASTCT Mehdi Hamadani, MD Mazyar Shadman, MD MPH Ambuj Kumar … pubmed.ncbi.nlm.nih.gov/40514010/

Just out! Latest NCCN guidelines has added daratumumab as Category 1 recommendation for high risk smoldering myeloma. In AQUILA trial, daratumumab: -Delayed progression to active myeloma -Delayed time to needing full myeloma therapy -Better overall survival

#Myeloma Paper of the Day: Del(17p), t(4;14), t(14;16), but not 1q+ are high-risk cytogenetic abnormalities (HRCAs) in primary #PCL; HRCA, elevated LDH, thrombocytopenia have highest OS impact & can create simple algorithm stratifying pPCL patients: pubmed.ncbi.nlm.nih.gov/40660267/. #mmsm

Just out! Current Risk stratification of all Plasma Cell Disorders. MGUS, SMM, Myeloma, Amyloidosis. We paid Open Access fees so you can download and read freely! Lots of Tables. Bookmark. Saurabh Zanwar Shaji Kumar Leukemia Journal Link: nature.com/articles/s4137…

Important: Belantamab (Blenrep) approved in Canada and Europe for relapsed myeloma. Belantamab is an important addition to the treatments we have. Despite the negative ODAC vote and concerns about dosing and corneal toxicity, I hope it is approved in the US as well.

On this week's episode of Tomorrow’s Cure, we examine how at-home cancer care is redefining treatment delivery—and what it means for patients, providers, and the future of care. Learn more: mayocl.in/4o7tL1d

Management recommendations for kidney transplantation in patients with plasma cell dyscrasia - Kidney International kidney-international.org/article/S0085-…

Some (yes we have a lot more) members of the Mayo Clinic Myeloma group at the #IMS25 meeting in Toronto.

Breaking: And I’m glad. This is an important option we need for patients with myeloma. FDA has approved belantamab in combination with bortezomib and dex (BVd) for relapsed or refractory multiple myeloma in patients who have received at least two prior lines of therapy,

3) Do we need to screen for MGUS No. And please do not check for M protein unless there is a good reason to. There is a screening trial iSTOPMM going on. If it shows benefit we will change our guidance. Till then screening of general population is not recommended.